scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1009013634 |
P356 | DOI | 10.1385/CRIAI:29:3:281 |
P698 | PubMed publication ID | 16391403 |
P50 | author | Yehuda Shoenfeld | Q1515807 |
P2093 | author name string | Michal Harel | |
P2860 | cites work | Practice parameter: Immunotherapy for Guillain-Barre syndrome: Report of the Quality Standards Subcommittee of the American Academy of Neurology | Q22241630 |
Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases | Q33659032 | ||
Immune mediated neuropathies--an update on therapeutic strategies | Q34302018 | ||
Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days | Q35463309 | ||
Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. | Q35551988 | ||
Guillain-Barré syndrome: epidemiology, pathophysiology and management | Q35690159 | ||
Intravenous immunoglobulin in autoimmune neuromuscular diseases | Q35776725 | ||
The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile | Q35832478 | ||
Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over IVIg in patients with axonal involvement | Q36016791 | ||
Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies | Q40585603 | ||
Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial | Q44738594 | ||
Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration | Q47376638 | ||
High‐dose immunoglobulin therapy for Guillain−Barré syndrome in Japanese children | Q53854440 | ||
Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody | Q56772330 | ||
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group | Q68081121 | ||
Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome | Q70831688 | ||
Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome | Q70894587 | ||
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome | Q71444464 | ||
Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group | Q73028007 | ||
Outcome of severe Guillain-Barré syndrome in children: comparison between untreated cases versus gamma-globulin therapy | Q73206373 | ||
P433 | issue | 3 | |
P921 | main subject | Guillain–Barré syndrome | Q205214 |
P304 | page(s) | 281-287 | |
P577 | publication date | 2005-12-01 | |
P1433 | published in | Clinical Reviews in Allergy & Immunology | Q1932354 |
P1476 | title | Intravenous immunoglobulin and Guillain-Barré syndrome | |
P478 | volume | 29 |
Q34117850 | Guillain-Barré syndrome (GBS). |
Q58861212 | Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain–Barré syndrome patients |
Q37828450 | The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally |
Search more.